MapLight Therapeutics, Inc. Depreciation
MapLight Therapeutics, Inc. (MPLT) reported Depreciation of $309.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-13
- MapLight Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $147.00K, a 8.09% increase year-over-year.
- MapLight Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $162.00K, a 2.41% decline year-over-year.
- MapLight Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $140.00K, a 27.84% decline year-over-year.
- MapLight Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $100.00K, a 50.00% decline year-over-year.
- MapLight Therapeutics, Inc. depreciation for fiscal 2025 was $578.00K, a 17.55% decline from fiscal 2024.
- MapLight Therapeutics, Inc. depreciation for fiscal 2024 was $701.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $309.00K 10-Q · filed 2026-08-13 | $449.00K derived: sum of 3 quarters · filed 2026-08-13 | $549.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $162.00K 10-Q · filed 2026-05-14 | $302.00K derived: sum of 2 quarters · filed 2026-05-14 | $402.00K derived: sum of 3 quarters · filed 2026-05-14 | $538.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $240.00K derived: sum of 2 quarters · filed 2026-03-26 | $376.00K derived: sum of 3 quarters · filed 2026-08-13 | $578.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $100.00K 10-Q · filed 2025-12-04 | $236.00K derived: sum of 2 quarters · filed 2026-08-13 | $438.00K 10-Q · filed 2025-12-04 | $596.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $302.00K 10-Q · filed 2026-08-13 | $496.00K derived: sum of 3 quarters · filed 2026-08-13 | $696.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $166.00K 10-Q · filed 2026-05-14 | $360.00K derived: sum of 2 quarters · filed 2026-05-14 | $560.00K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $394.00K derived: sum of 2 quarters · filed 2026-03-26 | $701.00K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $200.00K 10-Q · filed 2025-12-04 | $507.00K 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |